↓ Skip to main content

Cochrane Database of Systematic Reviews

Strontium ranelate for preventing and treating postmenopausal osteoporosis

Overview of attention for article published in Cochrane database of systematic reviews, October 2006
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
43 Dimensions

Readers on

mendeley
142 Mendeley
Title
Strontium ranelate for preventing and treating postmenopausal osteoporosis
Published in
Cochrane database of systematic reviews, October 2006
DOI 10.1002/14651858.cd005326.pub3
Pubmed ID
Authors

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY

Abstract

Strontium ranelate is a new treatment for osteoporosis therefore, its benefits and harms need to be known. To determine the efficacy and safety of strontium ranelate for the treatment and prevention of postmenopausal osteoporosis. We searched MEDLINE (1996 to March 2005), EMBASE (1996 to week 9 2005), the Cochrane Library (1996 to Issue 1 2005), reference lists of relevant articles and conference proceedings from the last two years. Additional data was sought from authors. We included randomized controlled trials (RCTs) of at least one year duration comparing strontium ranelate versus placebo reporting fracture incidence, bone mineral density (BMD), health related quality of life or safety in postmenopausal women. Treatment (versus prevention) population was defined as women with prevalent vertebral fractures and/or lumbar spine BMD T score < -2.5 SD. Two reviewers independently determined study eligibility, assessed trial quality and extracted the relevant data. Disagreements were resolved by consensus. RCTs were grouped by dose of strontium ranelate and treatment duration. Where possible, meta-analysis was conducted using the random effects model. Four trials met the inclusion criteria. Three included a treatment population (0.5 to 2 g of strontium ranelate daily) and one a prevention population (0.125 g, 0.5 g and 1 g daily). A 37% reduction in vertebral fractures (RR 0.63, 95% CI 0.56, 0.71) and a 14% reduction in non-vertebral fractures (RR 0.86, 95% CI 0.75, 0.98) were demonstrated over three years with 2 g of strontium ranelate daily in a treatment population. An increase in BMD was shown at all BMD sites after two to three years in both populations. Lower doses of strontium ranelate were superior to placebo and the highest dose demonstrated the greatest reduction in vertebral fractures and increase in BMD. An increased risk of diarrhea with 2 g of strontium ranelate was found; however, adverse events did not affect the risk of discontinuing treatment nor did it increase the risk of serious side effects, gastritis or death. Additional data suggests that the risk of vascular and nervous system side-effects is slightly increased with taking 2 g of strontium ranelate daily over three to four years. There is silver level evidence (www.cochranemsk.org) to support the efficacy of strontium ranelate for the reduction of fractures (vertebral and to a lesser extent non-vertebral) in postmenopausal osteoporotic women and an increase in BMD in postmenopausal women with/without osteoporosis. Diarrhea may occur however, adverse events leading to study withdrawal were not significantly increased with taking 2 g of strontium ranelate daily. Potential vascular and neurological side-effects need to be further explored.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 142 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 1%
Colombia 1 <1%
United States 1 <1%
Unknown 138 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 22 15%
Student > Master 21 15%
Researcher 19 13%
Student > Ph. D. Student 19 13%
Student > Postgraduate 8 6%
Other 27 19%
Unknown 26 18%
Readers by discipline Count As %
Medicine and Dentistry 67 47%
Nursing and Health Professions 8 6%
Psychology 6 4%
Biochemistry, Genetics and Molecular Biology 5 4%
Agricultural and Biological Sciences 4 3%
Other 21 15%
Unknown 31 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2018.
All research outputs
#3,718,625
of 13,370,991 outputs
Outputs from Cochrane database of systematic reviews
#6,655
of 10,570 outputs
Outputs of similar age
#72,984
of 278,983 outputs
Outputs of similar age from Cochrane database of systematic reviews
#173
of 251 outputs
Altmetric has tracked 13,370,991 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 10,570 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.9. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,983 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 251 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.